Art Collective teamLab to Open New Museum, teamLab Biovortex Kyoto on October 7, 2025
teamLab Biovortex Kyoto, art collective teamLab’s permanent art museum, is set to open in Minami-ku, Kyoto, as part of the Kyoto Station Southeast Area Project on October 7, 2025.
This will be teamLab's largest museum in Japan, spanning over 10,000 square meters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806347101/en/
Even if individual elements are separated in space and time, when a structural order appears among them, the elements transcend space and time and form a single entity. Despite significant changes in shape or size on the surface, or even if all of the elements are replaced, the single existence will be maintained. This spatiotemporal existence is part of the whole, it appears from the whole, and is returned to it. It is a living universe - a biocosmos. (teamLab, Morphing Continuum © teamLab)
In preparation for the museum’s opening, teamLab is in the process of creating several new artworks, including pieces that have never been exhibited in Japan. The first artworks that have been unveiled to be part of the new museum include, Massless Amorphous Sculpture, Morphing Continuum, The Eternal Universe of Words, The Way of Birds, and Forest of Resonating Lamps.
One of artworks that will be exhibited for the first time in Japan, Massless Amorphous Sculpture, is a floating immense sculpture created by a distinct environment that produces phenomena, based on teamLab’s concept of Environmental Phenomena. This piece is currently on view at exhibitions in Abu Dhabi, teamLab Phenomena, and Miami’s art center and will be unveiled in Japan for the first time.
Tickets are now available on the official website:
https://www.teamlab.art/e/kyoto/
This project, a collaboration with several companies based in Kyoto and Osaka, involves establishing and operating a facility on city-owned land in the southeastern area of Kyoto Station. The complex aims to be a "creative hub for generating and disseminating new value," with plans including a complex cultural facility featuring teamLab's art museum and an art center, among other attractions.
Through this project, teamLab aims to support Kyoto City's vision for urban development in the Kyoto Station Southeast Area, centered around culture, art, and youth. As the representative for this endeavor, teamLab will work alongside several partner companies with strong ties to Kyoto and Osaka.
teamLab Biovortex Kyoto
Opening October 7th, 2025
21-5 Higashikujo Higashi-Iwamotocho, Minami-ku, Kyoto
Ticket Prices
Adults (18 and above): JPY 3,800 ~
13–17 years: JPY 2,800
4–12 years: JPY 1,800
3 years and under: Free
Visitors with disabilities: 50% off the adult price
Flexible Pass (Admission time is not specified): JPY 12,000
*Tickets have designated dates/times.
*Tickets for adults and visitors with disabilities are subject to dynamic pricing, and prices will differ by day. Please purchase a ticket for the designated date/time upon checking the ticket price for the day.
*Tickets purchased on site at the museum will be +JPY 200 in addition to the above price.
Ticket
https://www.teamlab.art/e/kyoto/
For Media
Press Kit: https://www.dropbox.com/scl/fo/93lvrprtgnfgv7fetmdkh/AEWRAiT_cvPAO96U6t39MTo?rlkey=lthlq82v8w9ar71j3vyh3j6oq&st=b447so0p&dl=0
Teaser Video: https://youtu.be/I4U1qdtoyWY?feature=shared
Official Website: https://www.teamlab.art/e/kyoto/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250806347101/en/
Contacts
teamLab
E-mail: lab-pr-info@team-lab.com
Media Inquiries: https://forms.gle/LnSSKQtgXpSfrB917 -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fforms.gle%2FLn
SSKQtgXpSfrB917&esheet=54302055&newsitemid=20250806347101&lan=en-US&anchor=https
%3A%2F%2Fforms.gle%2FLnSSKQtgXpSfrB917&index=15&md5=441ba747c1ff521df2846508eb2f
c42e
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom